secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001193125-23-288019
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla holds KOL event on BA3011 Phase 2 NSCLC data; no specific results given
-------------------------------------------------------------------------------

- KOL event on Dec 4 featured Dr. Carl M. Gay (MD Anderson) discussing BA3011 (CAB-AXL-ADC) Phase 2 data in refractory NSCLC.
- Select slides from the presentation filed as Exhibit 99.1; no detailed efficacy or safety numbers provided in the filing.
- Company reiterates forward-looking statements; no guidance or material changes announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312523288019/0001193125-23-288019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312523288019/d630019d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-288019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer